Hikma is offering two new injectable products.
Bortezomib for injection 3.5 mg is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
[Read more: Hikma to acquire Custopharm]
Bortezomib injection had a market value of approximately $1 billion for the 12 months ending June 2022, according to IQVIA.
Hikma also launched fulvestrant injection 250 mg/5 ml.
The drug is indicated for the treatment of hormone-receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer in postmenopausal women.
[Read more: Hikma intros Kloxxado]
Fulvestrant injection had a market value of approximately $105 million in the 12 months ending June 2022, according to IQVIA.